TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31895776

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) individualized treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29794268

Group type: EXPERIMENTAL
Intervention: Lidocaine with methylprednisolone (LC-group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Lidocaine without methylprednisolone (LA-group)
Number of subjects: 136
Study: 30135888

Group type: EXPERIMENTAL
Intervention: Inflated education about ultrasound (EG)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Extra-inflated education about ultrasound (EEG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 67
Study: 25065710

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 2812

Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 2812
Study: 22220807

Group type: EXPERIMENTAL
Intervention: Scalp psoriasis (SP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Seborrheic dermatitis (SD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 42
Study: 21633535

Group type: EXPERIMENTAL
Intervention: Water infusion limited to the rectum, sigmoid colon and descending colon
Number of subjects: 179

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 179
Study: 20003758

Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exenatide administration 1 hour before MMTT
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of 3-month follow-up
Number of subjects: 11
Study: 16738289

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg(‐1) iv
Number of subjects: 40
Study: 15537991

Group type: EXPERIMENTAL
Intervention: Task-oriented physical therapy with rehabilitation technology (treadmill, Kinetron isokinetic exerciser, limb-load monitor)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Task-oriented physical therapy without rehabilitation technology
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Task-oriented physical therapy (both groups pooled)
Number of subjects: 63
Study: 11208940

Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (2.8 mmol)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeic acid (2.8 mmol)
Number of subjects: 7
Study: 10322887

Group type: EXPERIMENTAL
Intervention: Sanhuang Jiangtang recipe (SHJT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 95
Study: 8145656

Group type: EXPERIMENTAL
Intervention: Homoeopathic high dilutions of tobacco
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6362385

Group type: EXPERIMENTAL
Intervention: Surgical treatment (crossover group)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Medical treatment (medical adherers group)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Medical nonadherers (crossover group)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Surgical adherers (surgically randomized patients)
Number of subjects: 311
Study: 31697727

Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28
Study: 28763575

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rupatadine (all doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison with Caucasian subjects
Number of subjects: 27
Study: 26964877

Group type: EXPERIMENTAL
Intervention: Shortened, patient-designed informed consent document (5 pages)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Video informed consent format
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard paper informed consent document (17 pages)
Number of subjects: 201
Study: 25895304

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 22295891

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (2 g containing 600 mg EPA and DHA) for 9 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonsupplemented group (NSG)
Number of subjects: 23
Study: 20554982

Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral regimen
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Infant nevirapine prophylaxis
Number of subjects: 2369

Group type: COMPARATOR
Intervention: No extended postnatal antiretroviral regimen (control group)
Number of subjects: 2369
Study: 17913001

Group type: EXPERIMENTAL
Intervention: CPC/ZG mucoadhesive gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 80
Study: 17241421

Group type: EXPERIMENTAL
Intervention: UV-B irradiation after BoNT/A injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: BoNT/A injection (100 mU)
Number of subjects: 6
Study: 15058368

Group type: EXPERIMENTAL
Intervention: Gracey mini‐curettes (MiniFive)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gracey conventional curettes
Number of subjects: 10
Study: 10926345

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily
Number of subjects: 353

Group type: COMPARATOR
Intervention: Budesonide 800 microg twice daily
Number of subjects: 353
Study: 8885957

Group type: EXPERIMENTAL
Intervention: Low-saturated-fat, low-cholesterol diet
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Unrestricted diet (Control)
Number of subjects: 1062
Study: 1600111

Group type: EXPERIMENTAL
Intervention: Syrup formulations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Capsule formulations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both dosage forms
Number of subjects: 40
Study: 6364770

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 0
Study: 31398998

Group type: EXPERIMENTAL
Intervention: Comfort scores
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pain scores
Number of subjects: 100
Study: 28929919

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation therapy assisted walking (FES‐T)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional aerobic and resistance training (CONV)
Number of subjects: 34
Study: 25351866

Group type: EXPERIMENTAL
Intervention: Behavioral parent training (BPT) accessed via the Internet
Number of subjects: 307
Study: 24092833

Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ 4000 IU/d
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo (0 IU/d)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ 400 IU/d
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ (all doses)
Number of subjects: 323
Study: 21818647

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 60
Study: 19846212

Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal wipes during active labour and full-body chlorhexidine washes at birth
Number of subjects: 8011

Group type: COMPARATOR
Intervention: External genitalia water wipes during active labour and foot water washes at birth (Control)
Number of subjects: 8011
Study: 16140508

Group type: EXPERIMENTAL
Intervention: One-Stage group (n=32) received 12 months of inpatient treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Step-Down group (n=29) received 6 months of inpatient treatment followed by 12 months of outpatient therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (n=47) used routinely available services
Number of subjects: 108
Study: 14530727

Group type: EXPERIMENTAL
Intervention: Initial surgical resection
Number of subjects: 98

Group type: COMPARATOR
Intervention: Delayed resection after chemotherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 98

Group type: COMPARATOR
Intervention: Chemotherapy followed by resection
Number of subjects: 98

Group type: COMPARATOR
Intervention: Delayed operation excluding those who received only radiotherapy
Number of subjects: 98
Study: 10720081

Group type: EXPERIMENTAL
Intervention: GHRH (100 microg) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRH (100 microg) plus arginine (30 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: GHRH (100 microg) plus saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRH (100 microg) plus arginine
Number of subjects: 10
Study: 9121089

Group type: EXPERIMENTAL
Intervention: betapressin (penbutolol) 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: betapressin at a mean daily dose 108.4 +/- 6.25 mg
Number of subjects: 24
Study: 1527367

Group type: COMPARATOR
Intervention: Room air breathing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2% carbon dioxide gas mixture breathing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled hyperventilation
Number of subjects: 12
Study: 3965820

Group type: EXPERIMENTAL
Intervention: Cardioplegic solution infused via the aortic root
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reinfusions of cardioplegic solution given both centrally and through the completed distal left anterior descending anastomosis
Number of subjects: 68
Study: 30037301

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 124

Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 124
Study: 30388751

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 27555901

Group type: EXPERIMENTAL
Intervention: Locator bar attachment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Locator implant attachment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 24975729

Group type: EXPERIMENTAL
Intervention: Intracoronary injection with bone marrow mesenchymal stem cells (BMSCs) after PCI
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no BMSC transplantation)
Number of subjects: 58
Study: 21887732

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19996066

Group type: EXPERIMENTAL
Intervention: Treatment to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg
Number of subjects: 2699

Group type: COMPARATOR
Intervention: PAD patients
Number of subjects: 2699
Study: 17603828

Group type: EXPERIMENTAL
Intervention: Internet-based interactive asthma educational and monitoring program (Blue Angel for Asthma Kids)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Traditional asthma care plan (control group)
Number of subjects: 164
Study: 16116628

Group type: EXPERIMENTAL
Intervention: ruboxistaurin (RBX) mesylate
Number of subjects: 205
Study: 11147684

Group type: EXPERIMENTAL
Intervention: Reamed femoral nailing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unreamed femoral nailing
Number of subjects: 100
Study: 9726382

Group type: EXPERIMENTAL
Intervention: Olsalazine sodium, 3 g/day
Number of subjects: 168

Group type: COMPARATOR
Intervention: Mesalazine, 3 g/day
Number of subjects: 168
Study: 7973212

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 240
Study: 2564233

Group type: EXPERIMENTAL
Intervention: MC903 cream (1.2 mg MC903 per g cream)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 10
Study: 31044491

Group type: EXPERIMENTAL
Intervention: Low-dose factor VIII (FVIII) tertiary prophylaxis, 10 IU/kg body weight, two times per week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-dose factor VIII (FVIII) tertiary prophylaxis
Number of subjects: 50

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 50
Study: 29231349

Group type: EXPERIMENTAL
Intervention: Ear point embedding (Fugugou, Gan, Pizhixia, Shenmen) 30 minutes before anesthesia induction, applied until the end of surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received auricular tape applied at the same points without stimulation 30 minutes before anesthesia induction
Number of subjects: 50
Study: 25474552

Group type: EXPERIMENTAL
Intervention: Heparinized saline (10 U ml(-1))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 120
Study: 23076004

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 21245916

Group type: EXPERIMENTAL
Intervention: H58‐C clonal complex
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: H58‐E2 haplotype
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: H58‐C
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: H58‐E2
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: H58 S. Typhi
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: IncHI1 plasmid‐bearing S. Typhi H58‐C
Number of subjects: 267
Study: 18566548

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16822118

Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 12966367

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10852440

Group type: EXPERIMENTAL
Intervention: PTH (50, 75, or 100 microg recombinant human PTH‐(1‐84))
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily) after PTH treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PTH (highest dose)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PTH
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 66
Study: 9044492

Group type: COMPARATOR
Intervention: Group A (manikin training only)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group B (manikin and live patient training)
Number of subjects: 52
Study: 7804523

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 2895577

Group type: EXPERIMENTAL
Intervention: Betaxolol 10 to 40 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: Atenolol 25 to 100 mg
Number of subjects: 146
Study: 31383029

Group type: EXPERIMENTAL
Intervention: Biomarker-led care for HLA Ab+ participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care for HLA Ab+ participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA-Ab-unblinded group
Number of subjects: 0
Study: 28408020

Group type: EXPERIMENTAL
Intervention: IABP‐SHOCK II risk score categories (low, intermediate, high)
Number of subjects: 137
Study: 26615812

Group type: EXPERIMENTAL
Intervention: Multimedia education module (6-minute interactive module)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Verbal discussion alone (Control)
Number of subjects: 50
Study: 24097273

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg daily for 4 weeks followed by Tamsulosin 0.2 mg and Solifenacin 5.0 mg daily for 8 weeks (Group 1)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg and Solifenacin 5.0 mg combination for 12 weeks (Group 2)
Number of subjects: 156
Study: 22320148

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 561
Study: 19448566

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17298965

Group type: EXPERIMENTAL
Intervention: 6 g/day propionyl‐L‐carnitine (PLC) for 7 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (40 healthy individuals)
Number of subjects: 25
Study: 15347710

Group type: EXPERIMENTAL
Intervention: Superimposed images from coronary angiography and gated myocardial perfusion SPECT (MPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3D surface map generated from quantitative gated SPECT (QGS)/quantitative perfusion SPECT (QPS) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined angiographic images and 3D surface map
Number of subjects: 0
Study: 11884296

Group type: EXPERIMENTAL
Intervention: Dietary intervention (counseling for low-saturated fat, low-cholesterol diet)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1062
Study: 9791844

Group type: EXPERIMENTAL
Intervention: 200 mg Panax ginseng supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8566629

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 2790865

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste plus AmF/SnF2 mouthwash
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo toothpaste plus AmF/SnF2 mouthwash
Number of subjects: 92
Study: 322273

Group type: EXPERIMENTAL
Intervention: Tragant sulfate (pepsin inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinized liquorice extract
Number of subjects: 0
Study: 6947504

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study: 31587091

Group type: EXPERIMENTAL
Intervention: autologous bone marrow-derived culture-expanded MSCs (n=16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: autologous bone marrow-derived culture-expanded MSCs + PRP (n=14)
Number of subjects: 47

Group type: COMPARATOR
Intervention: corticosteroid (n=17)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 47
Study: 31623857

Group type: EXPERIMENTAL
Intervention: DL1 (trametinib 1.5 mg, GSK2141795 50 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: DL-1 (trametinib 1.5 mg, GSK2141795 25 mg)
Number of subjects: 26
Study: 29037544

Group type: EXPERIMENTAL
Intervention: Valsalva pushing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spontaneous pushing
Number of subjects: 80
Study: 26519230

Group type: EXPERIMENTAL
Intervention: Siponimod 2 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Siponimod 10 mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 23388502

Group type: EXPERIMENTAL
Intervention: Soluble maize fibre (SCF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SCF+P
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RS+P
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maltodextrin control
Number of subjects: 20
Study: 21836102

Group type: EXPERIMENTAL
Intervention: 10 days of bed rest (BR) in FDR subjects
Number of subjects: 13

Group type: COMPARATOR
Intervention: 10 days of bed rest (BR) in control (CON) subjects
Number of subjects: 13
Study: 19516032

Group type: COMPARATOR
Intervention: Short-term androgen suppression (6 months)
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Long-term androgen suppression (2.5 years)
Number of subjects: 970
Study: 17570983

Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily
Number of subjects: 30
Study: 15545306

Group type: EXPERIMENTAL
Intervention: DOV 216,303 at 150 mg (single dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: DOV 216,303 at 100 mg (multiple doses for 10 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: DOV 216,303 (single and multiple doses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: DOV 216,303 (doses > 10 mg)
Number of subjects: 13
Study: 12177637

Group type: EXPERIMENTAL
Intervention: Antidepressive treatment (mirtazapine, placebo-controlled); alternative treatment with citalopram if needed.
Number of subjects: 2140

Group type: COMPARATOR
Intervention: Care-as-usual (CAU); no treatment offered, psychiatric treatment outside the study recorded.
Number of subjects: 2140
Study: 10090926

Group type: COMPARATOR
Intervention: Cyclosporin (CSA) alone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combination of horse antithymocyte globulin (ATG) and cyclosporin (CSA)
Number of subjects: 115
Study: 8578271

Group type: EXPERIMENTAL
Intervention: Propiverine 15 mg/d
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Propiverine 30 mg/d
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Propiverine 45 mg/d
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Propiverine 60 mg/d
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Propiverine (15, 30, 45, 60 mg/d)
Number of subjects: 185
Study: 2084727

Group type: EXPERIMENTAL
Intervention: Homatropine hydrobromide (0.5% drops, two drops given twice spaced 15 minutes apart)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Homatropine hydrobromide
Number of subjects: 28
Study: 26519

Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg (20 mg twice daily) increased to a maximum of 560 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31306184

Group type: EXPERIMENTAL
Intervention: PEEP4 (PEEP 4 cmH2O)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PEEP8 (PEEP 8 cmH2O)
Number of subjects: 40
Study: 28577267

Group type: EXPERIMENTAL
Intervention: Cognitive training (CT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Active music therapy (AMT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Neuroeducation (NE)
Number of subjects: 39